NASDAQ:EFTRW eFFECTOR Therapeutics (EFTRW) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free EFTRW Stock Alerts $0.02 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.1652-Week Range$0.02▼$0.21Volume902 shsAverage Volume28,678 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get eFFECTOR Therapeutics alerts: Email Address Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About eFFECTOR Therapeutics Stock (NASDAQ:EFTRW)eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.Read More EFTRW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EFTRW Stock News HeadlinesFebruary 5, 2024 | finance.yahoo.comeFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 4, 2024 | thestreet.comeFFECTOR Therapeutics Inc. WarrantJanuary 9, 2024 | finance.yahoo.comeFFECTOR Therapeutics Announces Reverse Stock SplitJanuary 9, 2024 | finance.yahoo.comeFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024December 8, 2023 | seekingalpha.comeFFECTOR updates Phase 1/2 data for breast cancer therapyDecember 2, 2023 | markets.businessinsider.comBuy Rating for eFFECTOR Therapeutics Backed by FDA Fast Track and Promising Clinical DataNovember 30, 2023 | msn.comeFFECTOR Therapeutics 10% owner SR One Capital Management discloses sale of 609,163 sharesNovember 28, 2023 | finance.yahoo.comeFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast CancerNovember 27, 2023 | finanznachrichten.deeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 24, 2023 | benzinga.comeFFECTOR Therapeutics Stock (NASDAQ:EFTR), Analyst Ratings, Price Targets, PredictionsNovember 24, 2023 | benzinga.comeFFECTOR Therapeutics Stock (NASDAQ:EFTR) Dividends: History, Yield and DatesNovember 19, 2023 | thestreet.comeFFECTOR Therapeutics Inc.November 15, 2023 | finance.yahoo.comeFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual MeetingNovember 13, 2023 | finance.yahoo.comeFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 6, 2023 | finance.yahoo.comeFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare ConferenceOctober 24, 2023 | finance.yahoo.comeFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid LeukemiaSee More Headlines Receive EFTRW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:EFTRW CUSIPN/A CIK1828522 Webeffector.com Phone18589258215FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Stephen T. Worland Ph.D. (Age 66)CEO, President & Director Comp: $873.96kMr. Michael Byrnes M.B.A. (Age 47)Chief Financial Officer Comp: $654.82kDr. Douglas Warner M.D. (Age 52)Chief Medical Officer Comp: $660.16kDr. Davide Ruggero Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardDr. Kevan M. Shokat Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors EFTRW Stock Analysis - Frequently Asked Questions How have EFTRW shares performed in 2024? eFFECTOR Therapeutics' stock was trading at $0.1475 at the beginning of the year. Since then, EFTRW shares have decreased by 86.4% and is now trading at $0.0201. View the best growth stocks for 2024 here. How do I buy shares of eFFECTOR Therapeutics? Shares of EFTRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EFTRW) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe Next Industry Being Reshaped By AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetryMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
